rp-8-bromo-pet-cyclic gmps (sodium salt) ; rp-8-br-pet-cgmps hydrate, rp-β-phenyl-1,n2-etheno-8-bromoguanosine 3',5'-cyclic monophosphorothioate hydrate sodium salt ; rp-8-bromo-beta-phenyl-1,n2-ethenoguanosine 3',5'-cyclic monophosphorothioate sodium salt hydrate ; 9h-imidazo[1,2-a]purin-9-one,2-bromo-3,4-dihydro-3-[3,5-o-[(r)-mercaptophosphinylidene]-b-d-ribofuranosyl]-6-phenyl-,monosodium salt (9ci) ; rp-8-bromo-β-phenyl-1,n2-ethenoguanosine 3':5'-cyclic monophosphorothioate hydrate sodium salt ; rp-8-br-pet-cgmps hydrate, rp-β-phenyl-1,n2-etheno-8-bromoguanosine 3',5'-cyclic monophosphorothioate hydrate sodium salt ; rp-8-bromo-beta-phenyl-1,n2-ethenoguanosine 3',5'-cyclic monophosphorothioate sodium salt hydrate ; rp-8-bromo-β-phenyl-1,n2-ethenoguanosine 3':5'-cyclic monophosphorothioate hydrate sodium salt
Description
Rp-8-Br-PET-cGMPS is metabolically stable, competitive inhibitor of cGKI (Ki = 30 nM) and cGKII (cGMP-dependent protein kinase G) and blocks cGMP-gated retinal type ion channels (IC50 = 25 μmol).